"HHS Roundup: Regulatory Freeze, Medicare Drug Pricing, and Avian Flu Preparedness"

Welcome to this week's update on the Department of Health and Human Services (HHS). The most significant headline this week is the regulatory freeze issued by President Trump, which includes rescinding several executive actions by the outgoing Biden Administration and establishing the Department of Government Efficiency (DOGE)[1]. Let's dive into some key developments. HHS has been busy with several policy changes and implementation updates. For instance, CMS announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations, including diabetes and weight-loss drugs like Ozempic and Wegovy[1]. Additionally, HHS released an issue brief examining Medicare Part B enrollee use and spending on biosimilars between 2018 and 2023[1]. In terms of new initiatives, HHS and USDA are holding a public meeting to gather input on the Scientific Report of the 2025 Dietary Guidelines Advisory Committee. The public comment period for two reports on alcohol and health is also open until February 14, 2025[5]. On the public health front, the CDC issued a Health Alert Network (HAN) Health Advisory following sporadic human infections with avian influenza A(H5N1) viruses. The advisory recommends accelerated subtyping of influenza A specimens among hospitalized patients to prevent delays in identifying human infections with avian influenza A(H5N1) viruses[3]. These developments have significant impacts on American citizens, particularly those relying on Medicare and Medicaid services. For businesses and organizations, the regulatory freeze and changes in Medicare Part D drug pricing could have financial implications. State and local governments will need to adapt to these changes and ensure continuity of care for their residents. As for upcoming events, the Medicaid and CHIP Payment and Access Commission (MACPAC) is holding a public meeting on January 23 and 24, and the American Enterprise Institute (AEI) is hosting a discussion on the future of the Medicare Prescription Drug Benefit on January 23[1]. For more information, visit the HHS website and stay tuned for further updates. If you're interested in providing input on the Dietary Guidelines, make sure to submit your comments by February 14, 2025. Thank you for listening, and we'll see you next time. This content was created in partnership and with the help of Artificial Intelligence AI.